HER2-Driven Breast Cancer: Role of the Chaperonin HSP90 in Modulating Response to Trastuzumab-Based Therapeutic Combinations.

[ 52 ] found an association of borderline significance between worse DFS/OS and high HSP90 expression (synthesized in [ 50 ]); however, the latter study showed that these results pertained only to the triple-negative subgroup of patients and no association could be established in the HER2+ or HER2-negative/ER+ subgroups [ 52 ].

also in 2,624 other papers

Although, as expected, the combination of trastuzumab and pertuzumab achieved significant and borderline significant prolongation of PFS and OS, respectively, in the overall population, such an effect was particularly pronounced in the HSP90-high population.

also in 11,409 other papers